HERCON PHARMACEUTICALS, LLC

Balance Sheet

(STANDALONE)

December 31, 2019 (Unaudited)

| Assets | December 31, 2019 |
|---|----------------------|
| Current Accete | |
| Current Assets: Cash | \$150,421 |
| Accounts receivable | \$130,421 - |
| Other receivables | 840,388 |
| Inventory | 1,019,537 |
| Prepaid expenses | 231,246 |
| Deferred tax asset (short-term) | 6,600,165 |
| Total current assets | \$8,841,757 |
| Property and equipment, net | \$4,101,581 |
| Capital Work in Progress | 4,433,528 |
| Intellectual Property | 45,778 |
| Deferred Tax Asset (ZTL) | 1,449,756 |
| Total assets | \$18,872,400 |
| Liabilities and Stockholders' Equity | |
| Current liabilities | |
| Accounts payable | \$1,254,008 |
| Customer chargebacks, rebates, discounts and allowances | <u>-</u> |
| Accrued expenses | - |
| Short-term provisions | 467,000.00 |
| Deferred Revenue | - |
| Other liabilities | 774 |
| Total current liabilities | \$1,721,782 |
| Long term liabilities | |
| Loan - related party | \$39,024,893 |
| Deferred taxes | 239,116 |
| Valuation allowance | 6,365,963 |
| Total long term liabilities | \$45,629,972 |
| Total liabilities | \$47,351,754 |
| Stockholders' Equity | |
| Common stock, no par value | \$100,100 |
| Surplus (Deficit) | (28,579,454) |
| Total stockholders' equity | (\$28,479,354) |
| Total liabilities and stockholders' equity | \$18,872,400 |
| | |

Reviewed & Approved by

Ronald J. Burghauser Date
CFO

HERCON PHARMACEUTICALS, LLC

Statement of Operations

(STANDALONE)

For the period from January 1, 2019 through December 31, 2019 (Unaudited)

| | January 1, 2019 through December 31, 2019 | |
|--|--|-------------|
| Income | | |
| Gross sales | \$ | 1,539,133 |
| Total income | \$ | 1,539,133 |
| Adjustments | | |
| Returns & allowances | \$ | 1,864 |
| Total adjustments | \$ | 1,864 |
| Sales, Net | \$ | 1,537,268 |
| Cost of goods sold | | |
| Prime costs | \$ | 808,646 |
| Total cost of goods sold | \$ | 808,646 |
| Gross Profit | \$ | 728,622 |
| Operating expenses | | |
| Plant overhead | \$ | 4,093,089 |
| General and administrative | \$ | 1,443,387 |
| Depreciation and amortization | \$ | 606,792 |
| | \$ | 6,143,268 |
| Profit (Loss) from operations | \$ | (5,414,646) |
| Other income (expense) | | |
| Contract Reveune (ZTL) | \$ | 1,538,811 |
| Contract Reveune (outside 3rd parties) | \$ \$ \$ \$ | 371,274 |
| Income tax withholding (ZTL) | \$ | - |
| Financing-related expenses | \$ | (1,449,903) |
| Inventory Adjustments | \$ | (252.000) |
| Contingency for expenses | \$ | (252,000) |
| Total other income (expense) | · | 208,183 |
| Profit (Loss) before income taxes | \$ | (5,206,463) |
| Provision for income taxes | \$ | 780 |
| Net Profit (Loss) | \$ | (5,207,243) |

Reviewed & Approved by

Ronald J. Burghauser Date FEBRUARY 7, 2020

CFO

HERCON PHARMACEUTICALS, LLC

Statement of Cash Flows

(STANDALONE)

For the period from January 1, 2019 through December 31, 2019 (Unaudited)

| | January 1, 2019 through December 31, 2019 | |
|---|--|-------------|
| Cash flows from operating activities: | | |
| Net profit (loss) | \$ | (5,207,243) |
| Adjustments to reconcile net loss to cash used in operating activities: | | |
| Depreciation and amortization | \$ | 606,792 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | \$ | 27,818 |
| Other receivables | \$ | (215,484) |
| Inventories | \$ | 398,811 |
| Prepaid expenses | \$ | (8,114) |
| Deferred tax asset (short-term) | \$ | (1,068,733) |
| Deferred tax asset (ZTL) | \$ | (180,248) |
| Accounts payable | \$ | (1,138,335) |
| Customer chargebacks, rebates, discounts & allowances | \$ | - |
| Accrued expenses | \$ | - |
| Other liabilities | \$ | 70 |
| Short-term provisions | \$ | 252,000 |
| Deferred Revenue | \$ \$ | (50.054) |
| Deferred taxes (long-term liability) | \$ ¢ | (52,854) |
| Valuation allowance | \$ | 1,122,257 |
| Net cash used in operating activities | _\$ | (5,463,264) |
| Cash flows from investing activities: | ı | / · |
| Purchases of property and equipment | \$ | (1,343,554) |
| Net cash used in investing activities | \$ | (1,343,554) |
| Cash flows from financing activities: | | |
| Loan - related party | \$ | 6,879,893 |
| Net cash provided by financing activities | \$ | 6,879,893 |
| Net increase (decrease) in cash | \$ | 73,075 |
| Cash, beginning of period | \$ | 77,346 |
| Cash, end of period | \$ | 150,421 |
| cash, cha or period | | 100,721 |

Reviewed & Approved by

Ronald J. Burghauser Date TEBRUMNY 7, 7020

CFO

HERCON PHARMACEUTICALS, LLC Schedule of General and Administrative Expenses (STANDALONE)

For the period from January 1, 2019 through December 31, 2019 (Unaudited)

| | January 1, 2019 through December 31, 2019 | |
|---|--|--|
| Salaries and wages | \$ 791,006 | |
| Contribution to provident and other funds | \$ 19,330 | |
| Staff welfare expenses | \$ 148,608 | |
| Power & fuel (includes water bills & real estate taxes) | \$ 41,810 | |
| Refuse/waste disposal | \$ - | |
| Repairs to plant and machinery | \$ 167,914 | |
| Insurance | \$ - | |
| Traveling expenses/employee meals/company events | \$ 29,083 | |
| Legal and professional fees | \$ 68,085 | |
| Commission on sales | \$ - | |
| Freight, postage and forwarding on sales | \$ 13,739 | |
| Sales promotion expenses/website & hosting | \$ - | |
| Seminar, conference and exhibition | \$ 7,015 | |
| Analytical expenses | \$ 105,929 | |
| Office supplies | \$ 2,141 | |
| Payroll service charges | \$ 11,816 | |
| Recruiting expense | \$ 1,260 | |
| Relocation expense | \$ 17,140 | |
| Bank charges | \$ 1,998 | |
| Production supplies | \$ - | |
| Dues & subscriptions/registration fees | \$ 1,915 | |
| Telephone | \$ - | |
| Miscellaneous expenses | \$ 14,598 | |
| | \$ 1,443,387 | |

Reviewed & Approved by

Ronald J. Burghauser Date

CFO